Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DELTA 3 long-term safety of delgocitinib cream in chronic hand eczema
2020-002962-15Phase 3Completed
- Sponsor
- LEO Pharma
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of delgocitinib in chronic hand dermatitis (CHE), sponsored by LEO Pharma. Primary endpoint: Treatment-emergent adverse events. Started May 2021; status: completed.
02
Drugs
delgocitinib
03
Conditions
chronic hand dermatitis (CHE)
Beyond the preview
Go deeper on 2020-002962-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002962-15.